Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Clinical trial NCT04536922 · WITHDRAWN

Trial details

NCT number

NCT04536922

Sponsor

National Cancer Institute (NCI)

Status

WITHDRAWN

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2021-01-27

Primary completion

2021-01-27

Enrollment

0

View on ClinicalTrials.gov